academic article

• Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes..  Clinical cancer research : an official journal of the American Association for Cancer Research.  23:3794-3801. 2017
• TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer..  Nucleic acids research.  43:6945-6958. 2015
• Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer..  Cancer research.  74:3084-3091. 2014
• APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma..  Cancer research.  73:7222-7231. 2013
• Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel..  Human molecular genetics.  22:3038-3047. 2013
• Assessment of hepatocyte growth factor in ovarian cancer mortality..  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.  20:1638-1648. 2011
• Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary..  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.  24:277-287. 2011
• Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer..  Gynecologic oncology.  114:3-11. 2009
• Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer..  Journal of cellular biochemistry.  102:1117-1129. 2007
• Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity..  The Journal of clinical investigation.  116:1994-2004. 2006
• Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer..  Oncogene.  24:5089-5100. 2005